In vivo use of glutathione S-transferase activated nitric oxide donors


Ontology type: sgo:Patent     


Patent Info

DATE

N/A

AUTHORS

Paul Shami

ABSTRACT

The present invention provides for a method of simultaneously treating both cancer and the Multidrug Resistance Phenotype via inhibition of cellular thiols, such as Glutathione S-Transferase (GST). This enzyme is overproduced in leukemia and solid tumor cells and is one of the main pathways involved in the Multidrug Resistance phenotype. The treatment provides for the administration of a chemically inert pro-drug, designed to be a specific substrate for the GST enzyme that, once cleaved, liberates the bioactive toxin Nitric Oxide (NO) intracellularly at the site of a malignant growth. NO then acts to inhibit the growth of the malignant cells and to induce cellular differentiation and apoptosis therein, effectively treating an existing cancerous condition. Additionally, once NO is liberated from the pro-drug, the remaining structure acts to inhibit further GST activity, providing a treatment for the Multidrug Resistant phenotype. More... »

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3164", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/2581", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "name": "Paul Shami", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1093/jnci/92.17.1367", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004964591"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf01593790", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006434394", 
          "https://doi.org/10.1007/bf01593790"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1073/pnas.85.17.6518", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009922478"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0145-2126(95)00013-e", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017736752"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1023/a:1008247428385", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1056302744"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/83.11.757", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1059816512"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "description": "

The present invention provides for a method of simultaneously treating both cancer and the Multidrug Resistance Phenotype via inhibition of cellular thiols, such as Glutathione S-Transferase (GST). This enzyme is overproduced in leukemia and solid tumor cells and is one of the main pathways involved in the Multidrug Resistance phenotype. The treatment provides for the administration of a chemically inert pro-drug, designed to be a specific substrate for the GST enzyme that, once cleaved, liberates the bioactive toxin Nitric Oxide (NO) intracellularly at the site of a malignant growth. NO then acts to inhibit the growth of the malignant cells and to induce cellular differentiation and apoptosis therein, effectively treating an existing cancerous condition. Additionally, once NO is liberated from the pro-drug, the remaining structure acts to inhibit further GST activity, providing a treatment for the Multidrug Resistant phenotype.

", "id": "sg:patent.US-8404665-B2", "keywords": [ "vivo use", "glutathione S-transferases", "invention", "method", "Neoplasm", "multidrug resistance phenotype", "inhibition", "thiol", "Glutathione Transferase", "enzyme", "leukemia", "solid tumor", "main pathway", "Multiple Drug Resistance", "phenotype", "Organization and Administration", "pro-drug", "specific substrate", "nitric oxide", "malignant growth", "malignant cell", "cellular differentiation", "apoptosis", "condition" ], "name": "In vivo use of glutathione S-transferase activated nitric oxide donors", "recipient": [ { "id": "https://www.grid.ac/institutes/grid.223827.e", "type": "Organization" } ], "sameAs": [ "https://app.dimensions.ai/details/patent/US-8404665-B2" ], "sdDataset": "patents", "sdDatePublished": "2019-03-07T15:31", "sdLicense": "https://scigraph.springernature.com/explorer/license/", "sdPublisher": { "name": "Springer Nature - SN SciGraph project", "type": "Organization" }, "sdSource": "s3://com.uberresearch.data.dev.patents-pipeline/full_run_10/sn-export/5eb3e5a348d7f117b22cc85fb0b02730/0000100128-0000348334/json_export_0db08f31.jsonl", "type": "Patent" } ]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/patent.US-8404665-B2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/patent.US-8404665-B2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/patent.US-8404665-B2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/patent.US-8404665-B2'


 

This table displays all metadata directly associated to this object as RDF triples.

67 TRIPLES      14 PREDICATES      44 URIs      31 LITERALS      2 BLANK NODES

Subject Predicate Object
1 sg:patent.US-8404665-B2 schema:about anzsrc-for:2581
2 anzsrc-for:3164
3 schema:author N27fa3552c4f940fb85e389f0983249e4
4 schema:citation sg:pub.10.1007/bf01593790
5 https://doi.org/10.1016/0145-2126(95)00013-e
6 https://doi.org/10.1023/a:1008247428385
7 https://doi.org/10.1073/pnas.85.17.6518
8 https://doi.org/10.1093/jnci/83.11.757
9 https://doi.org/10.1093/jnci/92.17.1367
10 schema:description <p num="p-0001">The present invention provides for a method of simultaneously treating both cancer and the Multidrug Resistance Phenotype via inhibition of cellular thiols, such as Glutathione S-Transferase (GST). This enzyme is overproduced in leukemia and solid tumor cells and is one of the main pathways involved in the Multidrug Resistance phenotype. The treatment provides for the administration of a chemically inert pro-drug, designed to be a specific substrate for the GST enzyme that, once cleaved, liberates the bioactive toxin Nitric Oxide (NO) intracellularly at the site of a malignant growth. NO then acts to inhibit the growth of the malignant cells and to induce cellular differentiation and apoptosis therein, effectively treating an existing cancerous condition. Additionally, once NO is liberated from the pro-drug, the remaining structure acts to inhibit further GST activity, providing a treatment for the Multidrug Resistant phenotype.</p>
11 schema:keywords Glutathione Transferase
12 Multiple Drug Resistance
13 Neoplasm
14 Organization and Administration
15 apoptosis
16 cellular differentiation
17 condition
18 enzyme
19 glutathione S-transferases
20 inhibition
21 invention
22 leukemia
23 main pathway
24 malignant cell
25 malignant growth
26 method
27 multidrug resistance phenotype
28 nitric oxide
29 phenotype
30 pro-drug
31 solid tumor
32 specific substrate
33 thiol
34 vivo use
35 schema:name In vivo use of glutathione S-transferase activated nitric oxide donors
36 schema:recipient https://www.grid.ac/institutes/grid.223827.e
37 schema:sameAs https://app.dimensions.ai/details/patent/US-8404665-B2
38 schema:sdDatePublished 2019-03-07T15:31
39 schema:sdLicense https://scigraph.springernature.com/explorer/license/
40 schema:sdPublisher Nb99c247aa5f244089dc5e751084a0baa
41 sgo:license sg:explorer/license/
42 sgo:sdDataset patents
43 rdf:type sgo:Patent
44 N20f5917c5d1643178765becf1fa04157 schema:name Paul Shami
45 rdf:type schema:Person
46 N27fa3552c4f940fb85e389f0983249e4 rdf:first N20f5917c5d1643178765becf1fa04157
47 rdf:rest rdf:nil
48 Nb99c247aa5f244089dc5e751084a0baa schema:name Springer Nature - SN SciGraph project
49 rdf:type schema:Organization
50 anzsrc-for:2581 schema:inDefinedTermSet anzsrc-for:
51 rdf:type schema:DefinedTerm
52 anzsrc-for:3164 schema:inDefinedTermSet anzsrc-for:
53 rdf:type schema:DefinedTerm
54 sg:pub.10.1007/bf01593790 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006434394
55 https://doi.org/10.1007/bf01593790
56 rdf:type schema:CreativeWork
57 https://doi.org/10.1016/0145-2126(95)00013-e schema:sameAs https://app.dimensions.ai/details/publication/pub.1017736752
58 rdf:type schema:CreativeWork
59 https://doi.org/10.1023/a:1008247428385 schema:sameAs https://app.dimensions.ai/details/publication/pub.1056302744
60 rdf:type schema:CreativeWork
61 https://doi.org/10.1073/pnas.85.17.6518 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009922478
62 rdf:type schema:CreativeWork
63 https://doi.org/10.1093/jnci/83.11.757 schema:sameAs https://app.dimensions.ai/details/publication/pub.1059816512
64 rdf:type schema:CreativeWork
65 https://doi.org/10.1093/jnci/92.17.1367 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004964591
66 rdf:type schema:CreativeWork
67 https://www.grid.ac/institutes/grid.223827.e schema:Organization
 




Preview window. Press ESC to close (or click here)


...